Related Experiment Video
Updated: Aug 9, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia
Steven Nédellec1, Yves Renaudineau, Anne Bordron
1Institut de Synergie des Sciences et de la Santé, Brest University Medical School, Brest, France.
Insights
B-chronic lymphocytic leukemia (B-CLL) B cells show distinct surface IgM (sIgM) signaling pathways. Aberrant sIgM signaling correlates with prognosis, suggesting therapeutic potential.
Area of Science:
- Immunology
- Cell Signaling
- Oncology
Background:
- B-cell chronic lymphocytic leukemia (B-CLL) is characterized by aberrant B-cell signaling.
- Surface IgM (sIgM) cross-linking is a critical B-cell activation pathway.
Purpose of the Study:
- To investigate the distinct sIgM signaling pathways in B-CLL patients.
- To correlate sIgM signaling patterns with biological prognosis indicators.
Main Methods:
- Categorization of B-CLL cells based on sIgM cross-linking response (nonresponders vs. responders).
- Subclassification of responders based on proliferation or apoptosis.
- Analysis of intracellular signaling molecules including Ca2+ mobilization, PI3K, Akt, MAPK (ERK, p38), and Zap70.
- Assessment of tyrosine phosphorylation and lipid raft translocation.
- Correlation with clinical markers like CD38, IgVH gene mutations, CD79b, and clinical stage.
Main Results:
- B-CLL patients were divided into nonresponders (Group I) and responders (Group II).
- Responders were further classified into proliferating (IIa) and apoptotic (IIb) subgroups.
- Group I lacked Ca2+ mobilization, indicating signal disruption.
- Subgroup IIa showed constitutive PI3K and anti-mu induced Akt activation, with predominant ERK activation.
- Subgroup IIb exhibited p38 activation over ERK, and enhanced sIgM signaling via Zap70.
- Aberrant sIgM signaling correlated with high CD38, unmutated IgVH genes, full-length CD79b, and advanced clinical stage.
Conclusions:
- Distinct sIgM signaling pathways exist in B-CLL, differentiating responders from nonresponders and proliferating from apoptotic cells.
- Zap70 enhances sIgM signaling in the apoptotic subgroup (IIb).
- Modulating sIgM-induced signaling represents a potential therapeutic strategy for B-CLL.
Abstract:
On the basis of responses to surface IgM (sIgM) cross-linking, B cells from 41 patients with B-chronic lymphocytic leukemia were categorized as 15 nonresponders (group I) and 26 responders (group II). The latter cases were subclassified as those seven where proliferation was induced (subgroup IIa) and the remaining 19 in whom apoptosis occurred (subgroup IIa). Signal disruption in group I was confirmed by the absence of Ca2+ mobilization. Activation of PI3K was constitutive in subgroup IIa, but not in subgroup IIb, and that of Akt induced by anti-mu in subgroup IIa, but not in subgroup IIb. Among the MAPK, ERK was more highly activated relative to p38 in subgroup IIa, whereas activation of p38 predominated over that of ERK in subgroup IIb. For subgroup IIb cells, based on tyrosine phosphorylation and translocation into lipid rafts, sIgM signaling was shown to be enhanced by Zap70. The different consequences of signaling through sIgM were associated with biological prognosis indicators. These included high levels of CD38, lack of mutations in the IgVH chain genes, preferential usage of full-length CD79b, and severe clinical stage. Thus, modification of sIgM-induced signaling could be a therapeutic approach.
More Related Videos
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
Related Concept Videos
01:31Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:20Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
01:23Cells of the Adaptive Immune Response
01:28Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...